Hannes Snellman Counsel to Faron Pharmaceuticals Ltd in Its Public Share Offering of EUR 30.7 Million

Hannes Snellman acted as counsel to Faron Pharmaceuticals Ltd in its public share offering of EUR 30.7 million and the preceding issuance of convertible capital loans in the total amount of EUR 3.2 million and a private placement of EUR 4.8 million. Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatment of cancers via novel immunotherapies. Faron’s shares are listed on Nasdaq First North Growth Market Finland and as depositary interests, representing entitlements to shares, on AIM in the United Kingdom. The offering consisted of a public offering to private individuals and legal entities in Finland and an institutional offering to institutional investors internationally, and a separate open offer to qualifying holders of depositary interests in the United Kingdom and elsewhere and a retail offer to retail investors in the United Kingdom.

Hannes Snellman’s core advisory team comprised Riikka Rannikko, Anniina Järvinen, Tommi Kovero, Roope Sevon, Robert Gordin, Sofi Lehtinen, Aki Salmela, and Linnea Lehtonen (Capital Markets and Corporate), Josefina Aalto and Elisa Viiri (Finance), Jenni Parviainen (Tax), as well as Anni Nohteri and Melisa Göllü (Legal Assistants).